Free shipping on all orders over $ 500

SR3335

Cat. No. M5675
SR3335 Structure
Synonym:

ML 176

Size Price Availability Quantity
5mg USD 81  USD90 In stock
10mg USD 135  USD150 In stock
50mg USD 594  USD660 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

SR3335 suppresses the expression of endogenous RORα target genes in HepG2 involved in hepatic gluconeogenesis including glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. The first selective synthetic RORα inverse agonists may hold utility for suppression of elevated hepatic glucose production in type 2 diabetics.

Protocol
Cell Experiment
Cell lines HepG2 cells
Preparation method 16 h post-transfection, the cells were treated with vehicle or compound. 24 h post treatment, the luciferase activity was measured using the Dual-GloTM luciferase assay system.
Concentrations
Incubation time 24 h
Animal Experiment
Animal models 30 week old Diet induced obese (DIO) C57BL/6 male mice
Formulation 65% Kcal high-fat diet
Dosages 15 mg/kg
Administration i.p.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 405.34
Formula C13H9F6NO3S2
CAS Number 293753-05-6
Purity 97.49%
Solubility 10 mM in DMSO
Storage at -20°C
References

The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita.
Sadeghi H, et al. J Pathol. 2015 Sep;237(1):111-22. PMID: 25953430.

Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist.
Kumar N, et al. ACS Chem Biol. 2011 Mar 18;6(3):218-22. PMID: 21090593.

Related ROR Products
S18-000003

S18-000003 is a potent, effective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of 29 nM.

Neoruscogenin

Neoruscogenin is a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1).

Vimirogant

Vimirogant (also known as AGN-242428 and VTP-43742) is a potent, selective and orally active RORγt inhibitor.

GSK805

GSK805 is a potent, orally bioavailable RORγγ Inhibitor, with pIC50 of 8.4 and >8.2 for RORγ FRET assay and Th17 assay.

SR2211

SR2211 is a synthetic RORγ-selective modulator, functions as an inverse agonist, with a Ki of 105 nM and an IC50 of ~320 nM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: SR3335, ML 176 supplier, ROR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.